On July 29, 2010, Combs, Andrew Paul; Sparks, Richard B.; Yue, Eddy Wai Tsun; Hao, Feng; Bower, Michael Jason; Zhu, Wenyu published a patent.HPLC of Formula: 887581-09-1 The title of the patent was Preparation of oxatetraazatetracyclotricosanonaene derivatives and analogs for use as JAK and ALK inhibitors. And the patent contained the following:
Title compounds I [each A independently = CR3, N, O, S, etc.; each D independently = bond, N, O, S, etc.; each E independently = N, O, S, etc.; each L independently = bond, CH2, CH2O, etc., provided at least one is other than a bond; Q = (CR1R2)m; each X independently = N or CR3; R1 and R2 independently = H, halo, alkyl, etc.; or together with the c atom to which they are attached form an (un)substituted cycloalkyl or heterocycloalkyl; each R3 independently = H, halo, CN, alkyl, etc.; R4 = H, (un)substituted alkyl, arylalkyl, etc.; m = 1 to 4], and their pharmaceutically acceptable salts, are prepared and disclosed as janus kinase (JAK) and anaplastic lymphoma kinase (ALK) inhibitors. Thus, e.g., II路TFA was prepared by amination of 2,4,5-trichloropyrimidine with 3-methoxybenzylamine followed by amination with 3-aminobenzenemethanol, bromination, cyclization. Select I were evaluated in JAK1 kinase assays, e.g., II路TFA demonstrated an IC50 value of 51 nM. The experimental process involved the reaction of (2-Bromo-5-methoxyphenyl)methanamine(cas: 887581-09-1).HPLC of Formula: 887581-09-1
The Article related to oxatetraazatetracyclotricosanonaene derivative preparation janus kinase jak inhibitor, azatetracyclotricosanonaene oxatetra analog preparation anaplastic lymphoma kinase alk inhibitor and other aspects.HPLC of Formula: 887581-09-1
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem